Share

March 07, 2023; 100 (10) Research Article

Economic Evaluation of the Community Benefit of the Australian Pregnancy Register of Antiseizure Medications

Zanfina Ademi, Clara Marquina, Piero Perucca, Alison Hitchcock, Janet Graham, Mervyn J. Eadie, Danny Liew, Terence J. O'Brien, Frank J. Vajda
First published December 2, 2022, DOI: https://doi.org/10.1212/WNL.0000000000201655
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
37

Share

Article Information

vol. 100 no. 10 e1028-e1037
DOI: 
https://doi.org/10.1212/WNL.0000000000201655
PubMed: 
36460471
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received June 3, 2022
  • Accepted in final form October 19, 2022
  • First Published December 2, 2022.

Article Versions

Copyright & Usage: 
© 2022 American Academy of Neurology

Author Disclosures

    1. Zanfina Ademi, MPharm, MPH, PhD,
    2. Clara Marquina, PhD,
    3. Piero Perucca, MD, PhD,
    4. Alison Hitchcock, BSN,
    5. Janet Graham, BSN,
    6. Mervyn J. Eadie, PhD,
    7. Danny Liew, PhD,
    8. Terence J. O'Brien, MD and
    9. Frank J. Vajda, MD
  1. Zanfina Ademi, MPharm, MPH, PhD,
    2. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Clara Marquina, PhD,
    3. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Piero Perucca, MD, PhD,
    4. Scientific Advisory Boards:

    1. (1) Supernus Pharmaceuticals (advisory board honorarium to my department)(2) Chiesi (advisory board honorarium to my department)(3) Eisai (advisory board honorarium to my department)

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Sun Pharmaceutical Industries Ltd, speaker honorarium to my department(2) Eisai, speaker honorarium to my department(3) UCB, speaker honorarium to my department(4) Novartis, speaker honorarium to my department(5) LivaNova, speaker honorarium to my department(6) Chiesi, speaker honorarium to my department(7) The limbic, speaker honorarium to my department

    Editorial Boards:

    1. (1) Epilepsia Open, Associate Editor, 2018-present(2) Neurobiology of Disease, Editorial Board Member, 2019-present(3) Neurological Research and Practice, Editorial Board Member, 2020-2021

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) National Health and Medical Research Council, APP1163708, PI, 2019-present(2) Shenzhen government, SZSM201812005, CI, 2018-present(3) Medical Research Future Fund, APP2007707, CI, 2021-present(4) National Health and Medical Research Council, APP2012287, CI, 2022-present

    Research Support, Academic Entities:

    1. (1) The University of Melbourne(2) Monash University (Establishment grant)(3) Royal Melbourne Hospital (Victor Hurley Medical Research Grant in Aid)

    Research Support, Foundations and Societies:

    1. (1) Sylvia and Charles Viertel Charitable Foundation VIERCI2018014(2) Brain Foundation(3) Epilepsy Foundation(4) Royal Australasian College of Physicians(5) Weary Dunlop Medical Research Foundation(6) Brain Australia(7) Norman Beischer Medical Research Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Alison Hitchcock, BSN,
    5. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Janet Graham, BSN,
    6. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Mervyn J. Eadie, PhD,
    7. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. Editorial Board of CNS Drugs - for many years

    Patents:

    1. NONE

    Publishing Royalties:

    1. Eadie, MJ (2012) Headache through the centuries. New York. Oxford University Press. Some royalties received.Scott, Eadie A, Lees A. (2012) William Richard Gowers (1845-1915) - exploring the Victorian brain. Oxford. Oxford University Press. Some royalties received.Eadie MJ, Vajda FJE (2016) Antiepileptic drugs and pregnancy. Adis (Springer). No royalties received 92016)

    Employment, Commercial Entity:

    1. Private neurology consultant practice.University Chair now Emeritus

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Danny Liew, PhD,
    8. Scientific Advisory Boards:

    1. (1) Commercial entities. Participation in advisory boards for Edwards Lifesciences and Pfizer.(2) Non-profit entities. Past participation in advisory boards for Federal and State Departments of Health in Australia.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. (1) British Journal of Clinical Pharmacology, Reviews Editor, 7 years.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Commercial entity: Edwards Lifesciences.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Research support from the National Health and Medical Research Council of Australia, the Medical Research Future Fund of Australia and the Victorian Department of Health.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Terence J. O'Brien, MD and
    9. Scientific Advisory Boards:

    1. Medical Advisory Board, EisaiMedical Advisory Board, UCBMedical Advisory Board, LivaNovaMedical Advisory Board, SupernusMedical Advisory Board, LivaNova

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) UCB Pharma, speaker and advisory board, consulting contract with my institution; (2) Eisai, speaker and advisory board, consulting contract with my institutionhonoraria, (3) Liva Nova, speaker and advisory board, consulting contract with my institution

    Editorial Boards:

    1. (1) Epilepsy and Behavior (2009-17), 2), British Journal of Clinical Pharmacology (2011-17), 3) Epilepsia Open (2016-17), 4) Epilepsia

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Zynerba pharmaceuticals - medical monitor

    Speakers' Bureaus:

    1. Speaker fees for Eisai, UCB, LivaNova

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) UCB; (2) Zynerba; (3) Sanofi, (4)Janssen-Cilag; (5) Eisai; (6) LivaNova; (7) ES Theraputics; (8) Epidarex; (9) Supernus; (10) BioGen

    Research Support, Government Entities:

    1. NHMRC Project grants (Australia) 2006-18; NHMRC Centre for Research Excellence Grant (2011-16), NIH (2016-22), NHMRC Program Grant 2016-20. NHMRC Investigator Grant 2019-23; Medical Research Future Fund (MRFF) Grants 2019-24; US Department of Defence (DoD) (2021-24)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. RMH Neuroscience Foundation 2008-18

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Frank J. Vajda, MD
    10. Scientific Advisory Boards:

    1. (1) Director of the Australian Pregnancy Register(2) Member of the Central Project Commission of the International League against Epilepsy - EURAP the European Register of Antiepileptic Drugs

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Funding was provided to the Australian Pregnancy Register from Sanofi-Synthelabo, UCB Pharma, Janssen Cilag, Novartis, Pfizer and Glaxo. I am the Director of the Australian Pregnancy Register.

    Research Support, Government Entities:

    1. Australian Research Council, Partner Investigator, LP0669648, 2006-2009

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Funding was provided to the Australian Pregnancy Register from the Epilepsy Society of Australia.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Centre for Medicine Use and Safety (Z.A., C.M.), Faculty of Pharmacy and Pharmaceutical Sciences, School of Public Health and Preventive Medicine (Z.A., D.L.), Department of Neuroscience (Z.A., P.P., T.J.O.B.), Central Clinical School, Monash University, Melbourne; Epilepsy Research Centre (P.P.), Department of Medicine (Austin Health), The University of Melbourne; Bladin-Berkovic Comprehensive Epilepsy Program (P.P.), Department of Neurology, Austin Health, Melbourne; Department of Neurology (P.P., T.J.O.B.), Alfred Health, Melbourne; Department of Neurology (P.P., A.H., J.G., T.J.O.B., F.J.V.), The Royal Melbourne Hospital; Department of Medicine (M.J.E.), The University of Queensland, Brisbane; Adelaide Medical School (D.L.), University of Adelaide, South Australia; and Department of Medicine (The Royal Melbourne Hospital) (T.J.O.B., F.J.V.), The University of Melbourne, Australia.
  1. Correspondence
    Dr. Ademi zanfina.ademi{at}monash.edu
View Full Text

Article usage

Article usage: December 2022 to April 2023

AbstractFullPdfSource
Dec 2022513011Highwire
Jan 202321500Highwire
Feb 20239606Highwire
Mar 20233913419Highwire
Apr 20234831Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me